All News about Ipsen S.A. ADR
![](https://images.pexels.com/photos/4033021/pexels-photo-4033021.jpeg?auto=compress&cs=tinysrgb&dpr=1&w=500)
![](https://cdn.benzinga.com/files/images/story/2024/06/11/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
Exposures
Product Safety
![](https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/09/19/aapharma_13.png?width=1200&height=800&fit=crop)
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://cdn.benzinga.com/files/images/story/2023/08/21/exel.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/06/30/cbay.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/06/30/gnft.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/05/22/icpt_0.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png)
![](https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png)
![](https://mms.businesswire.com/media/20230126005858/en/1151926/5/Ipsen_Logo.jpg)
![](https://mms.businesswire.com/media/20230120005252/en/1151926/5/Ipsen_Logo.jpg)
![](https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png)
![](https://g.foolcdn.com/editorial/images/716571/person-in-a-lab-looking-through-a-microscope.jpg)
![](https://g.foolcdn.com/editorial/images/715824/merger-gettyimages-952625346.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/01/09/20230104_jp-morgan_ipsen-com_346x346pix.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20230108005085/en/1151926/5/Ipsen_Logo.jpg)
![](https://mms.businesswire.com/media/20221223005208/en/1151926/5/Ipsen_Logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/09/logo_dark__c424d3ab0271f3cf1e0eea9f187b0781.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221208005640/en/1151926/5/Ipsen_Logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/11/09/logo_light__2e9aa9b32f52b9da70343aa274f3a000.png?width=1200&height=800&fit=crop)
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
Via Benzinga
![](https://mms.businesswire.com/media/20221108006021/en/1151926/5/Ipsen_Logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/11/01/biotech6.jpg?width=1200&height=800&fit=crop)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20221025005735/en/1151926/5/Ipsen_Logo.jpg)
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
October 25, 2022
From Ipsen
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2022/10/02/biotech13.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://mms.businesswire.com/media/20220812005287/en/1151926/5/Ipsen_Logo.jpg)
From Ipsen
Via Business Wire
![](https://mms.businesswire.com/media/20220804006066/en/1151926/5/Ipsen_Logo.jpg)
From Ipsen
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.